BR0014063A - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Info

Publication number
BR0014063A
BR0014063A BR0014063-5A BR0014063A BR0014063A BR 0014063 A BR0014063 A BR 0014063A BR 0014063 A BR0014063 A BR 0014063A BR 0014063 A BR0014063 A BR 0014063A
Authority
BR
Brazil
Prior art keywords
formulations
estramustine phosphate
pharmacological properties
parenteral use
improved pharmacological
Prior art date
Application number
BR0014063-5A
Other languages
Portuguese (pt)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0014063A publication Critical patent/BR0014063A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES PARA USO PARENTERAL DE FOSFATO DE ESTRAMUSTINA COM PROPRIEDADES FARMACOLóGICAS MELHORADAS". Uma formulação farmacêutica que compreende um carreador ou diluente parenteralmente aceitável, fosfato de estramustina, uma sulfoalquileter ciclodextrina e albumina humana. A formulação pode ser administrada de acordo com um regime de quimioterapia combinada em associação com um ou mais agentes quimioterápicos. A formulação também permite que o fosfato de estramustina seja administrado sem efeitos colaterais no local da injeção."FORMULATIONS FOR PARENTERAL USE OF STRAMUSTIN PHOSPHATE WITH IMPROVED PHARMACOLOGICAL PROPERTIES". A pharmaceutical formulation comprising a parenterally acceptable carrier or diluent, estramustine phosphate, a sulfoalkylether cyclodextrin and human albumin. The formulation may be administered according to a combined chemotherapy regimen in combination with one or more chemotherapeutic agents. The formulation also allows estramustine phosphate to be administered without side effects at the injection site.

BR0014063-5A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties BR0014063A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
BR0014063A true BR0014063A (en) 2004-06-29

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014063-5A BR0014063A (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (en)
JP (1) JP2003509355A (en)
KR (1) KR20020059405A (en)
CN (1) CN1177583C (en)
AU (1) AU777763B2 (en)
BR (1) BR0014063A (en)
CA (1) CA2385063A1 (en)
CZ (1) CZ2002943A3 (en)
EA (1) EA005308B1 (en)
GB (1) GB9921954D0 (en)
HK (1) HK1047227A1 (en)
HU (1) HUP0202621A2 (en)
IL (1) IL148409A0 (en)
MX (1) MXPA02002859A (en)
NO (1) NO20021306L (en)
NZ (1) NZ517631A (en)
PL (1) PL353954A1 (en)
SK (1) SK3452002A3 (en)
WO (1) WO2001019338A1 (en)
ZA (1) ZA200201743B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2012037704A1 (en) 2010-09-21 2012-03-29 Telefonaktiebolaget L M Ericsson (Publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
MXPA02002859A (en) 2003-07-21
EP1212040A1 (en) 2002-06-12
WO2001019338A1 (en) 2001-03-22
JP2003509355A (en) 2003-03-11
PL353954A1 (en) 2003-12-15
CN1374858A (en) 2002-10-16
IL148409A0 (en) 2002-09-12
NZ517631A (en) 2004-01-30
KR20020059405A (en) 2002-07-12
CA2385063A1 (en) 2001-03-22
CN1177583C (en) 2004-12-01
EA005308B1 (en) 2004-12-30
AU777763B2 (en) 2004-10-28
CZ2002943A3 (en) 2002-08-14
NO20021306D0 (en) 2002-03-15
GB9921954D0 (en) 1999-11-17
HUP0202621A2 (en) 2002-12-28
ZA200201743B (en) 2003-05-28
HK1047227A1 (en) 2003-02-14
AU6836300A (en) 2001-04-17
NO20021306L (en) 2002-04-24
SK3452002A3 (en) 2002-08-06
EA200200369A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
BR9911046A (en) Use of tricyclic antidepressants for local analgesia
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
TR200002299T2 (en) Epothilon compositions.
CY1105953T1 (en) COMPOSITIONS FOR RELEASE OF DRUG COMBINATIONS
BR0014071A (en) Formulations for parenteral use of estramustine phosphate and amino acids
TR200003108T2 (en) Pharmaceutical compositions
HK1036969A1 (en) Compounds and compositions for delivering active agents
NZ501235A (en) Topical compositions containing emulsion of a discontinuous phase which is an eutectic mixture of two pharmaceutical agents and a continuous phase
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
SV2002000137A (en) PHARMACEUTICAL PRODUCTS BETA-CARBOLINA REF N. 29342/36539 EL
DE60137960D1 (en) PHARMACEUTICAL COMPOSITIONS WITH CORTICOSTEROIDES AND ANTI-INFECTIVES
BR0008468A (en) Method for human in vitro fertilization, use of a hypothalamic hormone and / or pituitary hormone or an agonist or antagonist of the same or an active derivative thereof, pharmaceutical kit in single dosage form, and any new aspect or combination of aspects
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
BR0008228A (en) Compositions of n-benzoyl staurosporine spontaneously dispersible
BR0014062A (en) Formulations for parenteral use of estramustine phosphate and sulfoalkylether cyclodextrins
ATE378070T1 (en) COMPOSITION WITH FULVESTRANT
BR0014063A (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GT200100063A (en) THE USE OF COMPOSITIONS BASED ON ANTIBIOTICS OF AZALIDES TO TREAT OR PREVENT A BACTERIAL INFECTION OR PROTOZOARY IN MAMMALS
NO20020631L (en) Formulations for parenteral use of estramustine phosphate and albumin
PT1058544E (en) INHIBITION OF TNF ACTIVITY
BR0010092A (en) Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation
BR0112035A (en) novispirin antimicrobial peptides
IT1318485B1 (en) USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH IONIMETALLIC COMPLEXES IN THE DIAGNOSTIC DISPLAY OF MICROVASCULAR SYSTEMS
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate
Ross et al. Fates of translocated cougars, Felis concolor, in Alberta

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.